Cisplatin and Etoposide with Concurrent Radiotherapy in Locally Advanced Thymic Carcinoma

Cisplatin and Etoposide with Concurrent Radiotherapy in Locally Advanced Thymic Carcinoma

___

  • 1. Shimosato Y, Kameya T, Nagai K, Suemasu K. Squa- mous cell carcinoma of the thymus. An analysis of eight cases. Am J Surg Pathol 1977;1(2):109–21.
  • 2. Venuta F, Rendina EA, Longo F, De Giacomo T, Anile M, Mercadante E, et al. Long-term outcome after mul- timodality treatment for stage III thymic tumors. Ann Thorac Surg 2003;76(6):1866–72; discussion 1872.
  • 3. Bretti S, Berruti A, Loddo C, Sperone P, Casadio C, Tessa M, et al; Piemonte Oncology Network. Multi- modal management of stages III-IVa malignant thy- moma. Lung Cancer 2004;44(1):69–77.
  • 4. Kim ES, Putnam JB, Komaki R, Walsh GL, Ro JY, Shin HJ, et al. Phase II study of a multidisciplinary ap- proach with induction chemotherapy, followed by sur- gical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer 2004;44(3):369–79.
  • 5. Morio A, Nakahara K, Ohse Y, Tahara M, Goto T, Yaku- maru K et al. Efficacy of induction chemoradiotherapy in thymic cancer: report of a successful case and re- view of the literature. Int J Clin Oncol 2002;7:201–4.
  • 6. Shintani Y, Ohta M, Hazama K, Miyoshi S, Kagisaki K and Matsuda H: Thymic carcinoma successfully re- sected with superior vena cava after chemoradiother- apy. Jpn J Thorac Cardiovasc Surg 2001;49:717–21.
  • 7. Masaoka A, Monden Y, Nakahara K, Tanioka T. Fol- low-up study of thymomas with special reference to their clinical stages. Cancer 1981;48(11):2485–92.
  • 8. Fornasiero A, Daniele O, Ghiotto C, Piazza M, Fiore-Donati L, Calabró F, et al. Chemotherapy for invasive thymoma. A 13-year experience. Cancer 1991;68(1):30–3.
  • 9. Loehrer PJ Sr, Kim K, Aisner SC, Livingston R, Ein- horn LH, Johnson D, et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thy- moma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol 1994;12(6):1164–8.
  • 10. Giaccone G, Ardizzoni A, Kirkpatrick A, Clerico M, Sahmoud T, van Zandwijk N. Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the Euro- pean Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1996;14(3):814–20.
  • 11. Highley MS, Underhill CR, Parnis FX, Karapetis C, Rankin E, Dussek J, et al. Treatment of invasive thy- moma with single-agent ifosfamide. J Clin Oncol 1999;17(9):2737–44.
  • 12. Grassin F, Paleiron N, André M, Caliandro R, Bretel JJ, Terrier P, et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma. A French experi- ence. J Thorac Oncol 2010;5(6):893–7.
  • 13. Loehrer PJ Sr, Jiroutek M, Aisner S, Aisner J, Green M, Thomas CR Jr, et al. Combined etoposide, ifos- famide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an inter- group trial. Cancer 2001;91(11):2010–5.
  • 14. Albain KS, Swann RS, Rusch VW, Turrisi AT 3rd, Shep- herd FA, Smith C, et al. Radiotherapy plus chemo- therapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009;374(9687):379–86.
  • 15. Hanna N, Neubauer M, Yiannoutsos C, McGarry R, Arseneau J, Ansari R, et al; Hoosier Oncology Group; US Oncology. Phase III study of cisplatin, etopo- side, and concurrent chest radiation with or without consolidation docetaxel in patients with inopera- ble stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008;26(35):5755–60.
  • 16. Takada M, Fukuoka M, Kawahara M, Sugiura T, Yokoyama A, Yokota S, et al. Phase III study of con- current versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limit- ed-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002;20(14):3054–60.
Türk Onkoloji Dergisi-Cover
  • ISSN: 1300-7467
  • Yayın Aralığı: 4
  • Başlangıç: 2015
  • Yayıncı: Ali Cangül
Sayıdaki Diğer Makaleler

Pre-Treatment and Post-Treatment Neutrophil-to- Lymphocyte Ratio Predict Pathological Tumor Response and Survival in Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy

Ela DELİKGÖZ SOYKUT, Yasemin KEMAL, Eylem ODABAŞI, Nilgün ŞAHİN, Betül KESKİNKILIÇ YAĞIZ, İrem Melike YAZICIOĞLU, Süheyla AYTAÇ ARSLAN, Yıldız GÜNEY

Cisplatin and Etoposide with Concurrent Radiotherapy in Locally Advanced Thymic Carcinoma

Gonca HANEDAN USLU, Çağlar YILDIZ AKDENİZ, Nihat YEŞILIRMAK

Impairment of NK Cell Mediated Immune Surveillance Against Acute Myeloid Leukemia

Mohammed TAHA

Radiotherapy in Cancer Treatment During The Covid-19 Pandemic: One Year Results From Northeast Turkey

Özlem AYNACI, Lasif SERDAR, Sema RAKICI, Seher KAZAZ, Emine CANYILMAZ, Zümrüt BAHAT, Ahmet Yaşar ZENGİN

Investigation of 18F-FDG PET/CT Findings and CA-125 Levels in Ovarian Cancer Staging

Reşit AKYEL, Elife AKGÜN, Burak AKOVALI, Onur Erdem ŞAHİN, Sait SAĞER, Abdullah Serdar AÇIKGÖZ, Zübeyde Rana KAYA DÖNER, Kerim SÖNMEZOĞLU

Dosimetric and Radiobiological Evaluation of Radiation-induced Pulmonary Toxicity in the Esophageal Malignancy Using VMAT

Sanjib GAYEN, Shekhar ANAND, Sumanta MANNA, Sri Harsha KOMBATHULA, Sweta SONI, Akanksha SOLANKI, Sonal VARSHNEY, Puneet PAREEK

Comparative Study of Marketed and Novel Colloidal Formulation for Topical Delivery of 5-Fluorouracil to Skin Cancer Cells: Ex-Vivo Release Study and Cytotoxicity Analysis

Harish SHARMA, Gyanesh Kumar SAHU, Swarnali Das PAUL, Chanchal Deep KAUR

Oxidative Stress Has a Negative Effect on the Development and Progression of Bladder Cancer

Murat DEMİR, Canan DEMİR

Pattern of Recurrence and Survival Outcomes in Non-Metastatic Triple-Negative Breast Cancer; A Retrospective Analysis

Jayaraman KANNAN, Srigopal MOHANTY, Amit SAKLANI, Deepak GEORGE, Natarajan INGERSAL

Survivin As an Immunohistochemical Prognostic Biomarker in Colorectal Cancer: A Meta-Analysis

Sedef Hande AKTAŞ, Büşra EMİR, Dilara Fatma AKIN BALI, Ozan YAZICI